ASCO Genitourinary Cancer Updates: 2023 Review and Renew Lake Tahoe
Dr Mamta Parikh, MD, MS from UC Davis Health Comprehensive Cancer Center comments on some of the genitourinary cancer updates from ASCO GU: Stratifying patients for triplet intensification therapy in metastatic, castration-sensitive prostate cancer, rucaparib in patients with BRCA or ATM mutation, PARP inhibitor combinations, Keynote 057 and CheckMate 274 results in bladder cancer, nivolumab/cabozantinib combination in metastatic RCC.
Related Resources